Screener
Axsome Therapeutics AXSM EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
| Interest expense, net | (1,185) | (2,431) |
| Loss before income taxes | (64,542) | (59,413) |
| Income tax expense | — | — |
| Net loss | $(64,542) | $(59,413) |
| Net loss per common share, basic and diluted | $(1.26) | $(1.22) |
| Weighted average common shares outstanding, basic and diluted | 51,198,349 | 48,871,163 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's EPS (basic)?
- Axsome Therapeutics (AXSM) reported EPS (basic) of -$1.26 in Q1 2026.
- How has Axsome Therapeutics's EPS (basic) changed year-over-year?
- Axsome Therapeutics's EPS (basic) decreased by 3.3% year-over-year, from -$1.22 to -$1.26.
- What is the long-term trend for Axsome Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EPS (basic) has grown at a 1.5% compound annual growth rate (CAGR), from -$3.47 to -$3.68.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Axsome Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude